Briefing Paper on Proposed Re-classification Synthetic Cannabinoid Receptor Agonists (SCRAs)

Release's briefing paper on the proposed re-­classification of Synthetic Cannabinoid Receptor Agonists (SCRAs) as a Class A drug.

Issues explored include:

  • The current classification system
  • Tackling supply
  • The harmfulness of SCRAs and Re-classification
  • Alternatives to Re-classification